TickerFacts.

Company research / VSBC

Vitaspring Biomedical Co. Ltd. (VSBC)

Build a valuation ↗↓ Download CSV

SEC name VITASPRING BIOMEDICAL CO. LTD. · CIK 0001697884 · OTC · Services-Commercial Physical & Biological Research

  • Sector Services
  • Incorporated NV
  • Fiscal year ends Jan 31

For the year ended 2026-01-31, Vitaspring Biomedical Co. Ltd. reported revenue of $0. Over the twelve months to 2026-07-31, revenue was $0.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-09-17

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-07-31 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-07-31		2026-01-312025-01-312024-01-312023-01-312022-01-312021-01-312020-01-312019-01-312018-01-312017-01-31
Revenue$0$0$0$0$0$5.61M$248.2K$15.1K$17.2K$16.2K$0
Cost of Revenuen/a$0$0$0$3.33M$3.55M$136.0K$13.4K$3.5Kn/an/a
Gross Profitn/a$0$0$0-$3.33M$2.07M$112.2K$1.7K$13.7K$11.3K$0
Operating Income-$454.9K-$385.4K-$679.9K-$1.12M-$4.18M$1.13M$425.4K$6.9K-$22.4K-$6.4Kn/a
Depreciation & Amortizationn/an/a$10.0K$15.1Kn/an/an/an/an/an/an/a
EBITDAn/an/a-$670.0K-$1.10Mn/an/an/an/an/an/an/a
Net Income-$455.6K-$415.4K-$774.9K-$1.12M-$4.16M$909.6K$425.4K$6.9K-$22.4K-$6.4K-$45
EPS (Diluted)n/a$0.00$0.00-$0.01-$0.02$0.00n/an/an/an/an/a
Total Assets$14.8K$14.7K$14.4K$137.3K$765.9K$3.60M$189.4K$0$0$1.9K$0
Total Liabilities$4.68M$4.45M$4.03M$3.49M$3.16M$2.03M$93.0K$0$11.4K$12.9K$4.6K
Shareholders' Equity-$4.66M-$4.43M-$4.02M-$3.35M-$2.40M$1.58M$96.4Kn/a-$6.9K-$3.4K$3.0K
Cash & Equivalentsn/an/a$0$0n/a$107.2K$45.4K$0$105$5.2K$555
Operating Cash Flow$10.6K-$2.7K-$14.7K-$34.9K-$77.6K-$269.6K-$42.1K-$105-$34.2K$401-$4.0K
Capital Expendituresn/an/an/an/a$0$73.0Kn/an/an/an/an/a
Free Cash Flown/an/an/an/a-$77.6K-$342.6Kn/an/an/an/an/a
Shares Outstanding207.03M207.03M207.03Mn/a152.08M118.59M209.67M10.90M10.90Mn/an/a
Weighted Average Diluted Sharesn/a207.03M207.03M207.03M206.52M205.98M91.09M10.90M9.82M2.29M49.3K